Publicly listed Strides Pharma Science is to sell its manufacturing facility in Singapore for USD 15 million to Rxilient Biohub. Proceeds from the transaction will be utilized for debt reduction.
The Singapore manufacturing site was mothballed last year and has become redundant post the acquisition of the Chestnut Ridge, US manufacturing site.
Want to receive such news items in your inbox? Click Here to sign up for a trial.